Spectra WaveWriter™ Spinal Cord Stimulator System allows patients to combine therapeutic options and customize treatment
Peoria, IL (March 15th, 2018) – Prairie Spine is among the first pain clinics in Central Illinois to offer the Spectra WaveWriter™ Spinal Cord Stimulator System to patients with chronic pain. It’s the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception stimulation, two therapies used in providing pain relief. Paresthesia-based therapy provides pain relief with a light tingling sensation while sub-perception therapy works without that sensation.
Spinal cord stimulation (SCS) is an FDA approved non-opioid treatment option for people with chronic pain in the legs and back. The device sends low electrical pulses to the spinal cord that interrupt pain signals. Two thin wires, called leads, are implanted in the spine and powered by a rechargeable battery which is implanted in the chest.
With the Spectra WaveWriter System, patients can combine both of these therapies to target one specific area of pain or use each therapy as needed to best manage multiple areas of pain. Patients provide real-time feedback using the system’s remote control. The Spectra WaveWriter System was developed with more than a decade of clinical research focused on optimizing sub-perception stimulation and delivering multiple therapies intended for more effective, long-term pain relief.
“Everyone experiences pain differently and patients can sometimes become less responsive to therapy as their pain changes over time. The Spectra WaveWriter System is breakthrough technology that offers patients flexibility to meet their individual needs for lasting relief. Treatment options like this are important as we face the challenge of providing patients relief from pain without relying solely on opioids.”
More than 100 million Americans suffer from chronic pain and it is the number one cause of disability in adults in the U.S.1,2 SCS was introduced more than 40 years ago. Unlike most surgical procedures, it is reversible. Patients undergo a trial period allowing them to evaluate it before deciding to receive a permanent implant.
2Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education and research. Washington, DC: National Academies Press, 2011.
Sub-perception stimulation has been demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia-based and sub-perception therapy are available for clinician’s use throughout the patient’s experience and treatment with SCS.
Indications for Use: The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain. Associated conditions and etiologies may be: radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), arachnoiditis, multiple back surgeries. Contraindications, warnings, precautions, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical risks, or are pregnant. Refer to the Instructions for Use provided with the SCS System or ControlYourPain.com for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.